"Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral Sclerosis"
Latest Information Update: 12 Jun 2023
Price :
$35 *
At a glance
- Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
- Indications Critical illness; Motor neuron disease; Polyneuropathy; Sclerosis
- Focus Expanded access; Therapeutic Use
- Acronyms HBPLS
- 07 Apr 2021 New trial record